title: Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.
abstract: Recently, bendamustine has become an important agent in the treatment for patients with lymphoid malignancies. Although the drug has received approval for second-line therapy in indolent lymphoma, a growing body of evidence suggests its efficacy and safety in first-line use. The results of randomised and observational studies with bendamustine as front-line therapy in non-Hodgkin lymphoma (NHL) with emphasis on efficacy and toxicity are presented. Furthermore, completed and ongoing clinical trials evaluating upfront bendamustine effectiveness in combination with other agents are discussed. The review refers mainly to indolent lymphoma, mantle cell lymphoma and aggressive lymphoma, as the most commonly diagnosed NHL types. Finally, we elaborated on the safety profile of bendamustine and the perspectives of using the drug as a first-line therapy.
authors.affiliation: Department of Haematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, 84 Szamarzewski Street, 60-569, Poznan, Poland, lidia.gil@skpp.edu.pl.
authors.forename: Lidia
authors.initials: L
authors.lastname: Gil
authors.forename: Maciej
authors.initials: M
authors.lastname: Kazmierczak
authors.forename: Renata
authors.initials: R
authors.lastname: Kroll-Balcerzak
authors.forename: Mieczyslaw
authors.initials: M
authors.lastname: Komarnicki
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D011379:Prognosis
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride
references.citation: Br J Haematol. 2016 Oct;175(2):281-289
references.pmid: 27448091
references.citation: Ann Hematol. 2015 Apr;94(4):633-41
references.pmid: 25630297
references.citation: Haematologica. 2001 May;86(5):485-93
references.pmid: 11410411
references.citation: J Clin Oncol. 2008 Jan 10;26(2):204-10
references.pmid: 18182663
references.citation: Ann Hematol. 2012 Oct;91(10):1579-86
references.pmid: 22752146
references.citation: J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12
references.pmid: 16402269
references.citation: Lancet. 2013 Apr 6;381(9873):1203-10
references.pmid: 23433739
references.citation: Cancer. 2010 Jan 1;116(1):106-14
references.pmid: 19890959
references.citation: Clin Med Insights Oncol. 2011;5:145-56
references.pmid: 21695099
references.citation: Am J Hematol. 2012 Jun;87(6):604-9
references.pmid: 22615102
references.citation: Hematol Oncol. 2017 Dec;35(4):424-431
references.pmid: 27734524
references.citation: J Clin Oncol. 2013 Apr 10;31(11):1442-9
references.pmid: 23401442
references.citation: Semin Oncol. 2002 Aug;29(4 Suppl 13):4-11
references.pmid: 12170425
references.citation: Ann Oncol. 2011 Aug;22(8):1839-44
references.pmid: 21257672
references.citation: Leuk Lymphoma. 2012 Nov;53(11):2290-2
references.pmid: 22475324
references.citation: Semin Hematol. 2008 Apr;45(2):90-4
references.pmid: 18381103
references.citation: Clin Adv Hematol Oncol. 2013 Mar;11(3):184-8
references.pmid: 23598988
references.citation: Expert Rev Hematol. 2013 Oct;6(5):525-37
references.pmid: 24125522
references.citation: J Med Econ. 2014 Feb;17(2):111-24
references.pmid: 24308372
references.citation: Clin Cancer Res. 2008 Jan 1;14(1):309-17
references.pmid: 18172283
references.citation: Br J Haematol. 2013 Feb;160(3):321-30
references.pmid: 23150919
references.citation: J Clin Oncol. 2013 Jan 1;31(1):104-10
references.pmid: 23109692
references.citation: J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12
references.pmid: 16088404